The Pender Corporate Bond Fund continued its rebound from the summer’s lows, returning 0.4[1] in August. Download PDF The Fund’s return was bolstered by strong line-item performance in some high conviction credits including Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) 2% convertible notes of 2026, which rallied more than 10% due to a substantial reduction in the […]

